MOLGEN
The main aim of the project is to define the genetic and non−genetic risk factors predisposing to adverse drug reactions in order to develop strategies for individualisation of drug therapy to maximise benefits and minimise harms. Our aim therefore is to develop the concept of personalised medicines − although this is already used by physicians in daily practice, our approach by using the huge advances in genetics that have occurred recently will refine and improve on this process.
The purpose of this research is to (a) identify patients with different types of adverse drug reactions; (b) using blood or saliva samples obtained from these patients, identify genetic factors which predispose to adverse reactions. The net effect of our research will be the development of genetic tests which can help in predicting individual susceptibility to adverse reactions, and thereby prevent through testing before drug intake.
Key Contacts
Sarah Heslop - Study Co-ordinator Email: sarah.heslop@liv.ac.uk
Cerys Pennington - Study Co-ordinator Email: cerys.pennington@liv.ac.uk